Sanuwave Health Inc. received a patent issued by the U.S. Patent and Trademark Office entitled “Use of Pressure Waves for Stimulation, Proliferation, Differentiation and Post-Implantation Viability of Stem Cells.” The claims of the patent (patent number 8,728,809) relate to the use of shock waves for stimulation of proliferation inside the body of donor stem cells. The proliferated donor stem cells are then harvested for further laboratory proliferation to create either autologous or allogeneic transplant cells. In another step, shock waves are used to pre-treat the targeted location for tissue regeneration, to stimulate blood vessel formation and thus increase survival rate for transplanted stem cells. Furthermore, the methods of this patent include the application of shock waves after stem cell transplantation in the recipient area to accelerate and enhance tissue reconstruction. The patent life extends to August 2031.“This patent opens a totally new field for using our shock wave technology in the most advanced medical treatments that employ stem cells for tissue reconstruction,” commented Kevin Richardson, chairman of the board of directors of Sanuwave.
“The total market for stem cell research products, stem cell antibodies and stem cell therapies was $5.7 billion in 2011 and has a potential to reach $8.8 billion by 2016. Our technology can play a role in this market, especially since successful confirmatory work of the subject of this patent has been done by a team at Harvard University. Using Sanuwave’s devices in two different animal models, these scientists demonstrated the effects of shock waves on stimulation inside the body of donor stem cells, which were harvested, implanted and successfully produced viable tissue regeneration. This work has been published in two peer-reviewed journals,” concluded Richardson.
Sanuwave now has 38 patents (issued or pending) on focused shock waves in medical and non-medical applications.
Date: May 20, 2014
Source: Sanuwave Health
Filed Under: Drug Discovery
